According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The company reports revenue growth of 26% and PAT growth of 21% YoY
The study was conducted in patients with mild to moderate COVID-19
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
India business grew 11.8% YoY vs mid-single digit industry growth.
Subscribe To Our Newsletter & Stay Updated
